

116TH CONGRESS  
1ST SESSION

**S.** *Dianne Feinstein*

To expand research on the cannabidiol and marihuana.

---

IN THE SENATE OF THE UNITED STATES

---

Mrs. FEINSTEIN (for herself, Mr. GRASSLEY, Mr. SCHATZ, Mr. DURBIN, Ms. KLOBUCHAR, Mr. TILLIS, Mr. KAINE, Ms. ERNST, and Mr. CRAMER) introduced the following bill; which was read twice and referred to the Committee on \_\_\_\_\_

---

**A BILL**

To expand research on the cannabidiol and marihuana.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the  
5 “Cannabidiol and Marihuana Research Expansion Act”.

6 (b) TABLE OF CONTENTS.—The table of contents for  
7 this Act is as follows:

- Sec. 1. Short title; table of contents.
- Sec. 2. Definitions.

TITLE I—REGISTRATIONS FOR MARIHUANA RESEARCH

- Sec. 101. Marihuana research applications.
- Sec. 102. Research protocols.
- Sec. 103. Applications to manufacture marihuana for research.

Sec. 104. Adequate and uninterrupted supply.

Sec. 105. Security requirements.

Sec. 106. Prohibition against reinstating interdisciplinary review process for non-NIH funded researchers.

TITLE II—DEVELOPMENT OF FDA-APPROVED DRUGS USING  
CANNABIDIOL AND MARIHUANA

Sec. 201. Medical research on cannabidiol.

Sec. 202. Registration for the commercial production and distribution of Food and Drug Administration approved drugs.

Sec. 203. Importation of cannabidiol for research purposes.

TITLE III—DOCTOR-PATIENT RELATIONSHIP

Sec. 301. Doctor-patient relationship.

TITLE IV—FEDERAL RESEARCH

Sec. 401. Federal research.

1 **SEC. 2. DEFINITIONS.**

2 In this Act—

3 (1) the term “appropriately registered” means  
4 that an individual or entity is registered under the  
5 Controlled Substances Act (21 U.S.C. 801 et seq.)  
6 to engage in the type of activity that is carried out  
7 by the individual or entity with respect to with a  
8 controlled substance on the schedule that is applica-  
9 ble to cannabidiol or marihuana, as applicable;

10 (2) the term “cannabidiol” means—

11 (A) the substance, cannabidiol, as derived  
12 from marihuana that has a  
13 tetrahydrocannabinol level that is greater than  
14 0.3 percent; and

15 (B) the synthetic equivalent of the sub-  
16 stance described in subparagraph (A);

1           (3) the terms “controlled substance”, “dis-  
2           pense”, “distribute”, “manufacture”, “marihuana”,  
3           and “practitioner” have the meanings given such  
4           terms in section 102 of the Controlled Substances  
5           Act (21 U.S.C. 802), as amended by this Act;

6           (4) the term “covered institution of higher edu-  
7           cation” means an institution of higher education (as  
8           defined in section 101 of the Higher Education Act  
9           of 1965 (20 U.S.C. 1001)) that—

10                   (A)(i) has highest or higher research activ-  
11                   ity, as defined by the Carnegie Classification of  
12                   Institutions of Higher Education; or

13                   (ii) is an accredited medical school or an  
14                   accredited school of osteopathic medicine; and

15                   (B) is appropriately registered under the  
16                   Controlled Substances Act (21 U.S.C. 801 et  
17                   seq.);

18           (5) the term “drug” has the meaning given the  
19           term in section 201(g)(1) of the Federal Food,  
20           Drug, and Cosmetic Act (21 U.S.C. 321(g)(1));

21           (6) the term “medical research for drug devel-  
22           opment” means medical research that is—

23                   (A) a preclinical study or clinical investiga-  
24                   tion conducted in accordance with section  
25                   505(i) of the Federal Food, Drug, and Cos-

1           metie Act (21 U.S.C. 355(i)) or otherwise per-  
2           mitted by the Department of Health and  
3           Human Services to determine the potential  
4           medical benefits of marihuana or cannabidiol as  
5           a drug; and

6                   (B) conducted by a covered institution of  
7           higher education, practitioner, or manufacturer  
8           that is appropriately registered under the Con-  
9           trolled Substances Act (21 U.S.C. 801 et seq.);  
10          and

11           (7) the term “State” means any State of the  
12          United States, the District of Columbia, and any  
13          territory of the United States.

## 14       **TITLE I—REGISTRATIONS FOR** 15       **MARIHUANA RESEARCH**

### 16       **SEC. 101. MARIHUANA RESEARCH APPLICATIONS.**

17          Section 303(f) of the Controlled Substances Act (21  
18       U.S.C. 823(f)) is amended—

19           (1) by redesignating paragraphs (1) through  
20           (5) as subparagraphs (A) through (E), respectively;

21           (2) by striking “(f) The Attorney General” and  
22           inserting “(f)(1) The Attorney General”;

23           (3) by striking “Registration applications” and  
24           inserting the following:

25           “(2)(A) Registration applications”;

1           (4) by striking “Article 7” and inserting the  
2 following:

3           “(3) Article 7”; and

4           (5) by inserting after paragraph (2)(A), as so  
5 designated, the following:

6           “(B)(i) The Attorney General shall register a practi-  
7 tioner to conduct research with marihuana if—

8           “(I) the applicant’s research protocol—

9           “(aa) has been reviewed and allowed—

10           “(AA) by the Secretary of Health and  
11 Human Services under section 505(i) of  
12 the Federal Food, Drug, and Cosmetic Act  
13 (21 U.S.C. 355(i));

14           “(BB) by the National Institutes of  
15 Health or another Federal agency that  
16 funds scientific research; or

17           “(CC) pursuant to sections 1301.18  
18 and 1301.32 of title 21, Code of Federal  
19 Regulations, or any successors thereto; and

20           “(II) the applicant has demonstrated to the At-  
21 torney General that there are effective procedures in  
22 place to adequately safeguard against diversion of  
23 the controlled substance for legitimate medical or  
24 scientific use pursuant to section 105 of the  
25 Cannabidiol and Marihuana Research Expansion

1 Act, including demonstrating that the security meas-  
2 ures are adequate for storing the quantity of mari-  
3 huana the applicant would be authorized to possess.

4 “(ii) The Attorney General may deny an application  
5 for registration under this subparagraph only if the Attor-  
6 ney General determines that the issuance of the registra-  
7 tion would be inconsistent with the public interest. In de-  
8 termining the public interest, the Attorney General shall  
9 consider the factors listed in—

10 “(I) subparagraphs (B) through (E) of para-  
11 graph (1); and

12 “(II) subparagraph (A) of paragraph (1), if the  
13 applicable State requires practitioners conducting re-  
14 search to register with a board or authority de-  
15 scribed in such subparagraph (A).

16 “(iii)(I) Not later than 60 days after the date on  
17 which the Attorney General receives a complete applica-  
18 tion for registration under this subparagraph, the Attor-  
19 ney General shall—

20 “(aa) approve the application; or

21 “(bb) request supplemental information.

22 “(II) For purposes of subclause (I), an application  
23 shall be deemed complete when the applicant has sub-  
24 mitted documentation showing that the requirements  
25 under clause (i) are satisfied.

1           “(iv) Not later than 30 days after the date on which  
2 the Attorney General receives supplemental information as  
3 described in clause (iii)(I)(bb) in connection with an appli-  
4 cation described in this subparagraph, the Attorney Gen-  
5 eral shall approve or deny the application.

6           “(v) If an application described in this subparagraph  
7 is denied, the Attorney General shall provide a written ex-  
8 planation of the basis of denial to the applicant.”.

9   **SEC. 102. RESEARCH PROTOCOLS.**

10          (a) IN GENERAL.—Paragraph (2)(B) of section 303  
11 of the Controlled Substances Act (21 U.S.C. 823(f), as  
12 amended by section 101 of this Act, is further amended  
13 by adding at the end the following:

14          “(vi)(I) If the Attorney General grants an application  
15 for registration under clause (i), the registrant may amend  
16 or supplement the research protocol without reapplying if  
17 the registrant does not change—

18                 “(aa) the quantity or type of drug;

19                 “(bb) the source of the drug; or

20                 “(cc) the conditions under which the drug is  
21 stored, tracked, or administered.

22          “(II)(aa) If a registrant under clause (i) seeks to  
23 change the type of drug, the source of the drug, or condi-  
24 tions under which the drug is stored, tracked, or adminis-  
25 tered, the registrant shall notify the Attorney General via

1 registered mail, or an electronic means permitted by the  
2 Attorney General, not later than 30 days before imple-  
3 menting an amended or supplemental research protocol.

4       “(bb) A registrant may proceed with an amended or  
5 supplemental research protocol described in item (aa) if  
6 the Attorney General does not explicitly object during the  
7 30-day period beginning on the date on which the Attorney  
8 General receives the notice under item (aa).

9       “(cc) The Attorney General may only object to an  
10 amended or supplemental research protocol under this  
11 subclause if additional security measures are needed to  
12 safeguard against diversion or abuse.

13       “(dd) If a registrant under clause (i) seeks to address  
14 additional security measures identified by the Attorney  
15 General under item (cc), the registrant shall notify the At-  
16 torney General via registered mail, or an electronic means  
17 permitted by the Attorney General, not later than 30 days  
18 before implementing an amended or supplemental research  
19 protocol.

20       “(ee) A registrant may proceed with an amended or  
21 supplemental research protocol described in item (dd) if  
22 the Attorney General does not explicitly object during the  
23 30-day period beginning on the date on which the Attorney  
24 General receives the notice under item (dd).

1           “(III) If a registrant under clause (i) seeks to change  
2 the quantity of marihuana needed for research, the change  
3 shall be deemed approved by the Attorney General on the  
4 date on which the registered mail return receipt is re-  
5 turned to the registrant, or the date on which the elec-  
6 tronic notification, as permitted by the Attorney General,  
7 is received, if the registrant submits to the Attorney Gen-  
8 eral—

9           “(aa) the Drug Enforcement Administration  
10 registration number of the registrant;

11           “(bb) the quantity of marihuana already ob-  
12 tained; and

13           “(cc) the quantity of additional marihuana  
14 needed to complete the research.

15           “(IV) Nothing in this clause shall limit the authority  
16 of the Secretary of Health and Human Services over re-  
17 quirements related to research protocols, including  
18 changes in—

19           “(aa) the method of administration of mari-  
20 huana;

21           “(bb) the dosing of marihuana; and

22           “(cc) the number of individuals or patients in-  
23 volved in research.”.

24           (b) REGULATIONS.—Not later than 1 year after the  
25 date of enactment of this Act, the Attorney General shall

1 promulgate regulations to carry out the amendment made  
2 by this section.

3 **SEC. 103. APPLICATIONS TO MANUFACTURE MARIHUANA**  
4 **FOR RESEARCH.**

5 (a) IN GENERAL.—Section 303 of the Controlled  
6 Substances Act (21 U.S.C. 823) is amended—

7 (1) by redesignating subsections (c) through (k)  
8 as subsections (d) through (l), respectively;

9 (2) by inserting after subsection (b) the fol-  
10 lowing:

11 “(c)(1)(A) As it relates to applications to manufac-  
12 ture marihuana for research purposes, if the Attorney  
13 General places a notice in the Federal Register to increase  
14 the number of entities registered under this Act to manu-  
15 facture marihuana to supply appropriately registered re-  
16 searchers in the United States, the Attorney General shall,  
17 not later than 60 days after the date on which the Attor-  
18 ney General receives a completed application—

19 (i) approve the application; or

20 (ii) request supplemental information.

21 “(B) For purposes of subparagraph (A), an applica-  
22 tion shall be deemed complete when the applicant has sub-  
23 mitted documentation showing each of the following:

24 (i) The requirements designated in the notice  
25 in the Federal Register are satisfied.

1           “(ii) The requirements under this Act are satis-  
2       fied.

3           “(iii) The applicant will limit the transfer and  
4       sale of any marihuana manufactured under this sub-  
5       section—

6           “(I) to researchers who are registered  
7       under this Act to conduct research with con-  
8       trolled substances in schedule I; and

9           “(II) for purposes of use in preclinical re-  
10       search or in a clinical investigation pursuant to  
11       an investigational new drug exemption under  
12       505(i) of the Federal Food, Drug, and Cos-  
13       metic Act (21 U.S.C. 355(i)).

14          “(iv) The applicant will transfer or sell any  
15       marihuana manufactured under this subsection only  
16       with prior, written consent for the transfer or sale  
17       by the Attorney General.

18          “(v) The applicant has completed the applica-  
19       tion and review process under subsection (a) for the  
20       bulk manufacture of controlled substances in sched-  
21       ule I.

22          “(vi) The applicant has established and begun  
23       operation of a process for storage and handling of  
24       controlled substances in schedule I, including for in-  
25       ventory control and monitoring security in accord-

1       ance with section 105 of the Cannabidiol and Mari-  
2       huana Research Expansion Act.

3           “(vii) The applicant is licensed by each State in  
4       which the applicant will conduct operations under  
5       this subsection, to manufacture marihuana, if that  
6       State requires such a license.

7           “(C) Not later than 30 days after the date on which  
8       the Attorney General receives supplemental information  
9       requested under subparagraph (A)(ii) with respect to an  
10      application, the Attorney General shall approve or deny  
11      the application.

12          “(2) If an application described in this subsection is  
13      denied, the Attorney General shall provide a written expla-  
14      nation of the basis of denial to the applicant.”;

15           (3) in subsection (h)(2), as so redesignated, by  
16      striking “subsection (f)” each place it appears and  
17      inserting “subsection (g)”;

18           (4) in subsection (j)(1), as so redesignated, by  
19      striking “subsection (d)” and inserting “subsection  
20      (e)”;

21           (5) in subsection (k), as so redesignated, by  
22      striking “subsection (f)” each place it appears and  
23      inserting “subsection (g)”.

24      (b) TECHNICAL AND CONFORMING AMENDMENTS.—

1           (1) The Controlled Substances Act (21 U.S.C.  
2           801 et seq.) is amended—

3           (A) in section 102 (21 U.S.C. 802)—

4           (i) in paragraph (16)(B)—

5           (I) in clause (i), by striking “or”  
6           at the end;

7           (II) by redesignating clause (ii)  
8           as (iii); and

9           (III) by inserting after clause (i)  
10          the following:

11          “(ii) the synthetic equivalent of hemp-de-  
12          rived cannabidiol that contains less than 0.3  
13          percent tetrahydrocannabinol; or”;

14          (ii) in paragraph (52)(B)—

15          (I) by striking “303(f)” each  
16          place it appears and inserting  
17          “303(g)”; and

18          (II) in clause (i), by striking  
19          “(d), or (e)” and inserting “(e), or  
20          (f)”; and

21          (iii) in paragraph (54), by striking  
22          “303(f)” each place it appears and insert-  
23          ing “303(g)”;

1 (B) in section 304 (21 U.S.C. 824), by  
2 striking “303(g)(1)” each place it appears and  
3 inserting “303(h)(1)”;

4 (C) in section 307(d)(2) (21 U.S.C.  
5 827(d)(2)), by striking “303(f)” and inserting  
6 “303(g)”;

7 (D) in section 311(h) (21 U.S.C. 831(h)),  
8 by striking “303(f)” each place it appears and  
9 inserting “303(g)”;

10 (E) in section 401(h)(2) (21 U.S.C.  
11 841(h)(2)), by striking “303(f)” each place it  
12 appears and inserting “303(g)”;

13 (F) in section 403(c)(2)(B) (21 U.S.C.  
14 843(c)(2)(B)), by striking “303(f)” and insert-  
15 ing “303(g)”;

16 (G) in section 512(c)(1) (21 U.S.C.  
17 882(c)(1)) by striking “303(f)” and inserting  
18 “303(g)”.

19 (2) Section 1008(e) of the Controlled Sub-  
20 stances Import and Export Act (21 U.S.C. 958(e))  
21 is amended—

22 (A) in paragraph (1), by striking “303(d)”  
23 and inserting “303(e)”;

24 (B) in paragraph (2)(B), by striking  
25 “303(h)” and inserting “303(i)”.

1 (3) Title V of the Public Health Service Act (42  
2 U.S.C. 290aa et seq.) is amended—

3 (A) in section 520E-4(c) (42 U.S.C.  
4 290bb-36d(c)), by striking “303(g)(2)(B)” and  
5 inserting “303(h)(2)(B)”; and

6 (B) in section 544(a)(3) (42 U.S.C.  
7 290dd-3(a)(3)), by striking “303(g)” and in-  
8 serting “303(h)”.

9 **SEC. 104. ADEQUATE AND UNINTERRUPTED SUPPLY.**

10 On an annual basis, the Attorney General shall assess  
11 whether there is an adequate and uninterrupted supply of  
12 marihuana, including of specific strains, for research pur-  
13 poses.

14 **SEC. 105. SECURITY REQUIREMENTS.**

15 (a) IN GENERAL.—An individual or entity engaged  
16 in researching marihuana or its components shall store it  
17 in a securely locked, substantially constructed cabinet.

18 (b) REQUIREMENTS FOR OTHER MEASURES.—Any  
19 other security measures required by the Attorney General  
20 to safeguard against diversion shall be consistent with  
21 those required for practitioners conducting research on  
22 other controlled substances in schedules I and II in section  
23 202(c) of the Controlled Substances Act (21 U.S.C.  
24 812(c)) that have a similar risk of diversion and abuse.

1 **SEC. 106. PROHIBITION AGAINST REINSTATING INTER-**  
2 **DISCIPLINARY REVIEW PROCESS FOR NON-**  
3 **NIH FUNDED RESEARCHERS.**

4 The Secretary of Health and Human Services may  
5 not—

6 (1) reinstate the Public Health Service inter-  
7 disciplinary review process described in the guidance  
8 entitled “Guidance on Procedures for the Provision  
9 of Marijuana for Medical Research” (issued on May  
10 21, 1999); or

11 (2) require another review of scientific protocols  
12 that is applicable only to research on marijuana or  
13 its components.

14 **TITLE II—DEVELOPMENT OF**  
15 **FDA-APPROVED DRUGS**  
16 **USING CANNABIDIOL AND**  
17 **MARIHUANA**

18 **SEC. 201. MEDICAL RESEARCH ON CANNABIDIOL.**

19 Notwithstanding any provision of the Controlled Sub-  
20 stances Act (21 U.S.C. 801 et seq.), the Safe and Drug-  
21 Free Schools and Communities Act (20 U.S.C. 7101 et  
22 seq.), chapter 81 of title 41, United States Code, or any  
23 other Federal law, an appropriately registered covered in-  
24 stitution of higher education, a practitioner, or a manufac-  
25 turer may manufacture, distribute, dispense, or possess  
26 marijuana or cannabidiol if the marijuana or cannabidiol

1 is manufactured, distributed, dispensed, or possessed, re-  
2 spectively, for purposes of medical research for drug devel-  
3 opment or subsequent commercial production in accord-  
4 ance with section 202.

5 **SEC. 202. REGISTRATION FOR THE COMMERCIAL PRODUC-**  
6 **TION AND DISTRIBUTION OF FOOD AND**  
7 **DRUG ADMINISTRATION APPROVED DRUGS.**

8 The Attorney General shall register an applicant to  
9 manufacture or distribute cannabidiol or marihuana for  
10 the purpose of commercial production of a drug containing  
11 or derived from marihuana that is approved by the Sec-  
12 retary of Health and Human Services under section 505  
13 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
14 355), in accordance with the applicable requirements  
15 under subsection (a) or (b) of section 303 of the Con-  
16 trolled Substances Act (21 U.S.C. 823).

17 **SEC. 203. IMPORTATION OF CANNABIDIOL FOR RESEARCH**  
18 **PURPOSES.**

19 The Controlled Substances Import and Export Act  
20 (21 U.S.C. 951 et seq.) is amended—

21 (1) in section 1002(a) (21 U.S.C. 952(a))—

22 (A) in paragraph (1), by striking “and” at  
23 the end;

24 (B) in paragraph (2)(C), by inserting  
25 “and” after “uses,”; and

1 (C) inserting before the undesignated mat-  
2 ter following paragraph (2)(C) the following:

3 “(3) such amounts of marihuana or cannabidiol  
4 (as defined in section 2 of the Cannabidiol and Mar-  
5 ihuana Research Expansion Act) as are—

6 “(A) approved for medical research for  
7 drug development (as such terms are defined in  
8 section 2 of the Cannabidiol and Marihuana Re-  
9 search Expansion Act), or

10 “(B) necessary for registered manufactur-  
11 ers to manufacture drugs containing marihuana  
12 or cannabidiol that have been approved for use  
13 by the Commissioner of Food and Drugs under  
14 the Federal Food, Drug, and Cosmetic Act (21  
15 U.S.C. 301 et seq.),”; and

16 (2) in section 1007 (21 U.S.C. 957), by amend-  
17 ing subsection (a) to read as follows:

18 “(a)(1) Except as provided in paragraph (2), no per-  
19 son may—

20 “(A) import into the customs territory of the  
21 United States from any place outside thereof (but  
22 within the United States), or import into the United  
23 States from any place outside thereof, any controlled  
24 substance or list I chemical, or

1           “(B) export from the United States any con-  
2           trolled substance or list I chemical,  
3           unless there is in effect with respect to such person  
4           a registration issued by the Attorney General under  
5           section 1008, or unless such person is exempt from  
6           registration under subsection (b).

7           “(2) Paragraph (1) shall not apply to the im-  
8           port or export of marihuana or cannabidiol (as de-  
9           fined in section 2 of the Cannabidiol and Marihuana  
10          Research Expansion Act) that has been approved  
11          for—

12           “(A) medical research for drug develop-  
13          ment authorized under section 201 of the  
14          Cannabidiol and Marihuana Research Expan-  
15          sion Act; or

16           “(B) use by registered manufacturers to  
17          manufacture drugs containing marihuana or  
18          cannabidiol that have been approved for use by  
19          the Commissioner of Food and Drugs under the  
20          Federal Food, Drug, and Cosmetic Act (21  
21          U.S.C. 301 et seq.).”.

1       **TITLE III—DOCTOR-PATIENT**  
2                               **RELATIONSHIP**

3       **SEC. 301. DOCTOR-PATIENT RELATIONSHIP.**

4           It shall not be unlawful for a State-licensed physician  
5 to discuss—

6           (1) the currently known potential harms and  
7           benefits of marihuana derivatives, including  
8           cannabidiol, as a treatment with the legal guardian  
9           of the patient of the physician if the patient is a  
10          child; or

11          (2) the currently known potential harms and  
12          benefits of marihuana and marihuana derivatives,  
13          including cannabidiol, as a treatment with the pa-  
14          tient or the legal guardian of the patient of the phy-  
15          sician if the patient is a legal adult.

16       **TITLE IV—FEDERAL RESEARCH**

17       **SEC. 401. FEDERAL RESEARCH.**

18          (a) IN GENERAL.—Not later than 1 year after the  
19 date of enactment of this Act, the Secretary of Health and  
20 Human Services, in coordination with the Director of the  
21 National Institutes of Health and the heads of other rel-  
22 evant Federal agencies, shall submit to the Caucus on  
23 International Narcotics Control, the Committee on the Ju-  
24 diciary, and the Committee on Health, Education, Labor,  
25 and Pensions of the Senate and the Committee on Energy

1 and Commerce and the Committee on the Judiciary of the  
2 House of Representatives a report on—

3 (1) the potential therapeutic effects of  
4 cannabidiol or marihuana on serious medical condi-  
5 tions, including intractable epilepsy;

6 (2) the potential effects of marihuana, includ-  
7 ing—

8 (A) the effect of increasing delta-9-  
9 tetrahydrocannabinol levels on the human body  
10 and developing adolescent brains; and

11 (B) the effect of various delta-9-  
12 tetrahydrocannabinol levels on cognitive abili-  
13 ties, such as those that are required to operate  
14 motor vehicles or other heavy equipment; and

15 (3) the barriers associated with researching  
16 marihuana or cannabidiol in States that have legal-  
17 ized the use of such substances, which shall in-  
18 clude—

19 (A) recommendations as to how such bar-  
20 riers might be overcome, including whether pub-  
21 lic-private partnerships or Federal-State re-  
22 search partnerships may or should be imple-  
23 mented to provide researchers with access to  
24 additional strains of marihuana and  
25 cannabidiol; and

1 (B) recommendations as to what safe-  
2 guards must be in place to verify—

3 (i) the levels of tetrahydrocannabinol,  
4 cannabidiol, or other cannabinoids con-  
5 tained in products obtained from such  
6 States is accurate; and

7 (ii) that such products do not contain  
8 harmful or toxic components.

9 (b) ACTIVITIES.—To the extent practicable, the Sec-  
10 retary of Health and Human Services, either directly or  
11 through awarding grants, contracts, or cooperative agree-  
12 ments, shall expand and coordinate the activities of the  
13 National Institutes of Health and other relevant Federal  
14 agencies to better determine the effects of cannabidiol and  
15 marihuana, as outlined in the report submitted under  
16 paragraphs (1) and (2) of subsection (a).